FDA, MHRA, and WADA status for research peptides. Updated monthly.
PEPTIDE
FDA STATUS
COMPOUNDING (US)
WADA
UK/MHRA
UPDATED
SemaglutideApproved (Rx)Limited*AllowedApproved (Rx)2026-03
TirzepatideApproved (Rx)Limited*AllowedApproved (Rx)2026-03
TesamorelinApproved (Rx)YesBannedNot approved2026-01
PT-141Approved (Rx)YesAllowedNot approved2025-12
BPC-157Not approvedBanned (503A/B)AllowedNot approved2026-01
TB-500Not approvedBanned (503A/B)BannedNot approved2025-12
IpamorelinNot approvedBannedBannedNot approved2025-10
CJC-1295Not approvedBannedBannedNot approved2025-10
SermorelinWithdrawnBannedBannedNot approved2025-10
GHRP-2Not approvedBannedBannedNot approved2025-10
GHRP-6Not approvedBannedBannedNot approved2025-10
Thymosin Alpha-1Not approvedYesAllowedNot approved2025-11
EpitalonNot approvedUnknownAllowedNot approved2025-09
SemaxNot approvedUnknownAllowedNot approved2025-09
RetatrutidePhase 3N/AAllowedPhase 32026-02
⚠ This tracker is for informational purposes only and does not constitute legal advice. Regulatory status changes frequently. Always verify current status with FDA.gov, MHRA.gov.uk, and wada-ama.org directly. Peptora is not liable for any decisions made based on this information.